Iovance Biotherapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
825 Industrial Rd Ste 400, San Carlos, C...Phone Number
(650) 260-7120Website
www.iovance.comRevenue
$325 MillionStock Symbol
IOVAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Iovance Biotherapeutics
Iovance Biotherapeutics, founded in 2007 and headquartered in San Carlos, California, is a biopharmaceutical company developing tumor-infiltrating lymphocyte therapies against cancer.Explore more
Iovance Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Iovance Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Iovance Biotherapeutics
Funding: Get notified immidiatlly once Iovance Biotherapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Iovance Biotherapeutics had a recent Job posting/layoffs
Check if Iovance Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Iovance Biotherapeutics recently announced quarterly report
Product Launch: Get notified when Iovance Biotherapeutics launches new products
Iovance Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Iovance Biotherapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Iovance Biotherapeutics
Compare insights from companies similar to Iovance Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Iovance Biotherapeutics
$325M
501-1,000
Public
$1.1B
2007
FV
Frederick VogtInterim CEO & General Counsel
$117M
501-1,000
Public
$250M
2015
Company Profile Activity
Activity Insights
Iovance Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Iovance Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Iovance Biotherapeutics.
Iovance Biotherapeutics financials insights
Gather financial insights about Iovance Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Share Placement
$21.6M
2014
Stock Offering
$34.5M
2015
Stock Offering
$73.6M
2016
Share Placement
$100M
2017
Stock Offering
$57.5M
2018
Stock Offering
$172.5M
Stock Offering
$252M
2025
Stock/Share Issuance
$350M
Iovance Biotherapeutics Tech Stack
A closer look at the technologies used by Iovance Biotherapeutics
See more technologies
Most Recent Scoops
Project
Iovance Biotherapeutics has announced plans to expand its Authorized Treatment Center network to at least 110 locations by year-end 2026, up from more than 95 currently, with community ATCs now representing approximately one-third of the network and expected to increase significantly over the coming quarters.
Capacity Planning, Healthcare Operations
Project
Iovance Biotherapeutics has reported that nearly 2,000 patients have received Iovance TIL therapies across commercial and clinical settings at hundreds of centers in the U.S. and in 30 countries, with a long-term vision to reach tens of thousands of patients.
Pharmaceuticals, Clinical Operations
Project
Iovance Biotherapeutics has reported that payers and plans covering more than 250 million lives have added AMTAGVI to their policies, with more than 75% of AMTAGVI patients covered by private payers. More than 95% of patients live within 200 miles of an Authorized Treatment Center, and the company's centralized commercial manufacturing process the only FDA-approved scaled process for TIL therapy delivers a turnaround time of 31 days or less.
Pharmaceuticals
Project
Iovance Biotherapeutics has announced that a new survival analysis from its clinical trial, presented at ASCO, estimated a 10-year overall survival rate of 46.7% for AMTAGVI responders, supported by published five-year durability data and real-world response rates exceeding 50% in patients with two or fewer prior lines of therapy. These data are driving earlier physician adoption of AMTAGVI, with a growing number of Authorized Treatment Centers reporting real-world outcomes that consistently meet or exceed clinical trial results.
Medical Research, Pharmaceuticals, Clinical Operations
Open Position
Iovance Biotherapeutics News & Media
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 20, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 240,135 shares of Iovance’s common stock to twenty new, nonIovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?
The healthcare stock is now up more than 130% this year.Iovance Biotherapeutics (IOVA) Pops 43% on Stellar Q2. Here’s What Comes Next
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) rocketed to a fresh 52-week high on Thursday, clocking as much as 47 percent gains, after management reported a 66 percent jump in revenues that signaled the strengthening demand for its treatment for advanced melanoma. In intra-day trading, the stock surged to its highest price of $6.39 before trimming gains to […]Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDTCompany ParticipantsSara Pellegrino - Senior Vice President of Investor...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Iovance Biotherapeutics
Sign Up For FreeTo access detailed company insights
Iovance Biotherapeutics, founded in 2007 and headquartered in San Carlos, California, is a biopharmaceutical company developing tumor-infiltrating lymphocyte therapies against cancer.... Read More
